ABOLOGIX awarded a two year Innosuisse Innovation

Geneva, Switzerland, Juy 24, 2020.

Abologix has been granted a 2 year Innosuisse Innovation project in collaboration with the University Hospital of Geneva (HUG). The HUG will be the research partner and Abologix the implementation partner.The collaboration plans to study the mechanism of action involved in arresting tumour growth through the selective blocking of Junction Adhesion Molecule JAM-C by monoclonal antibodies supplied by Abologix. These studies will lead to a deeper understanding of the molecular mechanisms of JAM-C blockage to inhibit growth and metastasis of certain lymphomas.

Winners in Stage III of the Venture Kick competition

Geneva, Switzerland, May 26, 2021. Abologix has been named one of the winners of the Venture Kick stage III start up competition. “We are extremely happy to have been selected by Venture Kick to recei

Winners in Stage II of the Venture Kick competition

Geneva, Switzerland, November 1, 2020. Abologix has been named one of the winners of the Venture Kick stage II start up competition. “We are very happy to have passed this important milestone in the V

Winners in Stage I of the Venture Kick competition

Geneva, Switzerland, June 10, 2020. Abologix has been named one of the winners of the Venture Kick stage I start up competition. “We are very pleased and honored to have been chosen by Ventur